'This thing has hijacked my mind': Woman reveals devastating impact of little-known disorder
While some may feel irritable or moody around their menstrual cycle, Kim Cormack, 36, feels like a totally different person.
Usually, she is bubbly and chatty with a zest for living life, but in the days and weeks leading up to her period, she struggled to recognise the person she was becoming.
"I'd just be so depressed and crying all of the time, and angry," Kim explains.
It took multiple years of being misunderstood and misdiagnosed before a friend's search on the internet found the answers she had been looking for.
She has premenstrual dysphoric disorder (PMDD), a complex condition which Kim says almost claimed her life.
"The last time it got really, really bad, I actually snuck out of the house at 10 o'clock at night. It was raining and I went to one of the local parks and just sat in the dark. I had a pocket full of sleeping tablets," says Kim, describing a time when her PMDD symptoms felt so debilitating, she wanted to end her own life.
"I find it hard to describe how I felt and what was going through my mind, because it didn't feel like me," she adds.
One in 20 women affected
PMDD is described as being a severe form of premenstrual syndrome, thought to be linked to heightened sensitivity to hormonal changes which occur during the menstrual cycle.
Despite affecting around one in 20 women in the UK, PMDD was only officially recognised by the World Health Organisation in 2019.
Symptoms can last up to three weeks of the monthly cycle leading up to a period.
The impact of the condition varies, but many will struggle with anger, anxiety and depression, which is so severe, it has a devastating impact on all aspects of their lives.
"So I quit my job," explains Kim. "I also ended my relationship... it has affected my social life for sure. I don't go out as much, I have to be around people that I really, really trust."
"This thing has hijacked my mind and makes these decisions, and it makes you so vulnerable as a person," adds Kim.
According to a global study commissioned by the International Association for Premenstrual Disorders (IAPMD) and published in BMC Psychiatry, of the 599 people surveyed with PMDD, 72% experienced active suicidal ideation at some point, while 34% had attempted suicide.
Dr Hannah Short, a GP and specialist in menopause and premenstrual disorders, says she has seen "a number of women" who have tried to take their lives "due to their severe PMDD".
"Sometimes this has been when they've not really understood what's been going on," Dr Short says.
"It's important that we do raise awareness of the links to the menstrual cycle and make young girls and women aware that it's not normal to have those feelings in the build-up to your period," she adds.
But it is a condition also misunderstood by those in the medical field, meaning support may not always be in reach.
Raising awareness of the misunderstood condition
This, says Phoebe Williams, is why she set up The PMDD project, a charity only created in the last year to raise awareness and train professionals.
"It's debilitating, it can be classed as a disability, yet there is no awareness out there. Therefore, we are not receiving the support that we deserve. That's why the stats for suicide are so high," explains Phoebe.
She says: "The government do need to take this seriously. They need to recognise it as a serious condition."
Treatment for PMDD varies, but it is usually helped with medicines and talking therapies.
A spokesperson for the Department for Health and Social Care said: "It is totally unacceptable that women are not getting the care they need and that their voices are not being heard.
"That is why we are reforming women's healthcare, placing women's equality at the heart of our agenda, and ensuring women's health is never again neglected.
"This government is also ensuring mental health gets the same focus as physical health by investing £26m in new mental health crisis centres, providing funding for 380,000 additional talking therapy appointments and recruiting 8,500 mental health workers."
Kim is doing what she can as a trustee of The PMDD project to raise awareness of the condition, in the hope it may save the lives of other women struggling with symptoms.
Since getting a diagnosis, she has seen brighter days and is learning how to live with PMDD with the help of medical professionals.
Her treatment includes undergoing a chemically induced menopause with side effects that need to be managed with daily doses of medication.
Thinking about womb removal
For now, she is managing, but in future she may have to consider an even more difficult decision: living life without a womb.
"It's always been on the cards that I might need to have a hysterectomy," explains Kim, but says it is not a decision she would be taking lightly.
She admits: "There have been thoughts in my head, where I am like, 'am I going to be a full woman? How am I going to feel? Am I going to hate myself further down the line for making this choice?'
"But I know it has to come back to: 'I am alive', that's what it has to be."
"It is a difficult decision, but I am looking forward to my life without this; maybe I can start enjoying my life again," she concludes.
Anyone feeling emotionally distressed or suicidal can call Samaritans for help on 116 123 or email jo@samaritans.org in the UK. In the US, call the Samaritans branch in your area or 1 (800) 273-TALK.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
33 minutes ago
- The Independent
Prescription paracetamol urgently recalled over contamination fears
Britons have been urged to check their painkillers after batches of prescription paracetamol were recalled due to contamination fears. The Medicines and Healthcare products Regulatory Agency (MHRA) issued a notice after a small number of pills were found to be 'discoloured'. The medicine affected is two batches of 500mg paracetamol tablets from Chelonia Healthcare Limited. This issue has been identified in batch 2312010, however as a precautionary measure, batch 2312011 is also being recalled to mitigate any risk while the investigation and analysis remain ongoing. The affected pills have the expiry date of November 2027 and were distributed earlier this year. The MHRA warned healthcare professionals to 'stop supplying the above batches immediately' and quarantine all remaining stock before returning it to their supplier. It told patients: 'Patients or carers should check to see if they have received tablets from the listed batches of paracetamol 500mg tablets. 'The batch number can be found on the label of the medicine bottle and on the outer carton. 'These tablets can only be obtained from a pharmacy with a prescription. The number of tablets you will have been given will vary depending on your prescription and you may have only received a small number of tablets. 'The tablets should be 'white capsule-shaped tablets, scored on one side', as per the patient information leaflet. If you find tablets that are discoloured in any way, in pots from the listed batches, please contact your pharmacist or the healthcare professional who dispensed your prescription.' Patients who may have taken the medication and experienced an "adverse reaction" are also urged to seek medical attention and report their symptoms via the MHRA Yellow Card scheme.
BBC News
44 minutes ago
- BBC News
Tackling racism a priority, says Norfolk and Suffolk NHS Trust
Tackling "pockets of racism" in an NHS mental health trust remained a "number one priority", its chair has Billingham, the chair of Norfolk and Suffolk NHS Foundation Trust (NSFT) based in Norwich, pledged to make changes following findings from a recent staff survey found evidence that disciplinary processes for staff from a black, Asian and minority ethnic background were "more draconian".The study based on the experiences of 100 members of staff was commissioned by NSFT, and also included allegations of nepotism and inequality. Ms Billingham said: "There is undoubtedly pockets of racism within our trust."We've brought in experts from across the country to help us diagnose, where it's happening, why it's happening and we've got this movement now, across our staff, to say we've got to stop talking about being an anti-racist organisation, we have to act."Some of the racism came from patients and directed towards staff, and some staff expressed there was no clear process for dealing with racist Billingham confirmed making improvements was a top priority for the trust and that changes were not about "woke politics" but about getting the best from staff for patients."We've got to create that environment where staff are not subjected to racism, whether it's shouted or whispered, whether direct or indirect, we've got to eradicate it and stamp it out," she said. The workforce race equality report also found staff felt there were significant discrepancies in recruitment, career progression, the disciplinary process and equal included allegations of "widespread and problematic nepotism" and a fear of speaking up or making the report, NSFT's leadership was accused of not understanding race, and senior leaders were accused of not Ms Billingham also commented on a recent Care Quality Commission inspection which took place at the was removed from "special measures" status in February after more than seven years, following improvements to the findings of inspectors' visit a few days ago are yet to be made public but the chair of the NSFT said: "It's the start of our improvement journey."I'm hoping that we don't slip back, sometimes we take two steps forward and one step back."I am really optimistic that we will get better and are getting better." Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
The Independent
an hour ago
- The Independent
More testing needed for genetic cancer risk as too many women ‘missed', experts say
A new study has revealed that families of some cancer patients are being denied the opportunity to learn about their potential cancer risk due to inconsistencies in genetic testing. Academics have warned that the absence of adequate testing for Lynch syndrome is leaving some cancer patients unaware of their risk of developing other cancers. Lynch syndrome, a rare hereditary condition, elevates the risk of cancers of the bowel, womb, and ovaries. It arises from a gene mutation affecting DNA error correction during replication, potentially leading to uncontrolled cell growth. NHS guidelines stipulate that patients with bowel or womb cancer should undergo tumour assessments for Lynch syndrome markers. The identification of these markers should prompt a referral for genetic testing, confirming the diagnosis and enabling access to support and guidance regarding cancer risks for both the patients and their families. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. They found that 91 per cent of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64 per cent) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48 per cent of those eligible went on to get the test. Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
